Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 3/20 | 0.44 |
| ▸ | GABRD | O14764 | 3/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.44 |
| ▸ | GABRE | P78334 | 3/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.44 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | KDM6B | O15054 | 3/20 | 0.36 |
| ▸ | KDM4A | O75164 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL971141 | 0.85 | HCAR2 (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL15309515 | 0.84 | CYP3A4 (0.36) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL27860338 | 0.82 | HMGCR (0.37) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL18989231 | 0.82 | CDC7 (0.36) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL20267445 | 0.82 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5951752 | 0.82 | HCAR2 (0.37) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL718165 | 0.81 | TSHR (0.40) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL20524643 | 0.81 | HCAR2 (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL20268740 | 0.80 | NOTUM (0.33) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29086057 | 0.80 | GABRR1 (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2797893-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2014-11-05 | — | — | EP | claimed |
| WO-2013101598-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-07-04 | — | — | WO | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0673783-B1 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORP (US) | 2000-07-05 | — | — | EP | claimed |
| US-12077507-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-09-03 | — | — | US | disclosed |
| US-20240262808-A1 | XANTHINE OXIDASE INHIBITOR | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2024-08-08 | — | — | US | disclosed |
| US-20240109845-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-04-04 | — | — | US | disclosed |
| EP-4335844-A1 | CLASS OF XANTHINE OXIDASE INHIBITORS | Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. (CN) | 2024-03-13 | — | — | EP | disclosed |
| CN-116621846-B | Bicyclic heterocycle and tricyclic heterocycle compounds, and preparation method and medical application thereof | 华润医药研究院（深圳）有限公司 | 2023-10-17 | — | — | CN | disclosed |
| CN-116621846-A | Bicyclic heterocycle and tricyclic heterocycle compounds, and preparation method and medical application thereof | 华润医药研究院（深圳）有限公司 | 2023-08-22 | — | — | CN | disclosed |
| WO-2023154519-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-7056934-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1654234-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-10 | — | — | EP | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2005042534-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20050038033-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
| WO-2005009965-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| US-6200981-B1 | FOR TREATING INFLAMMATORY DISEASES SUCH AS ASTHMA, INFLAMMATORY BOWEL DISEASE, PSORIASIS, RHEUMATOID ARTHRITIS, MYOCARDIAL ISCHAEMIA, CYSTIC FIBROSIS, ARTHEREOSCLEROSIS, RESTENOSIS, PERIDONTAL DISEASE, SEPTIC SHOCK, OSTEOARTHRITIS | ASTRAZENECA UK LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| US-5310918-A | 1-aryl-substituted azole, non-linear optical material and novel molecular crystal containing same and method and module for the conversion of light wavelength using same | FUJI PHOTO FILM CO., LTD. (JP) | 1994-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262808-A1 | XANTHINE OXIDASE INHIBITOR | XDH, PNPO, MPO | GABRP 3557/4885GABRD 3499/4885GABRA1 2716/4885 |
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | GABRP 1954/4885GABRD 1532/4885GABRA1 903/4885 |
| US-20050038033-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | GABRP 3004/4885GABRD 3995/4885GABRA1 3015/4885 |
| US-20240109845-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HRAS, KRAS, NRAS | GABRP 3806/4885GABRD 4392/4885GABRA1 4202/4885 |
| US-12077507-B2 | Compositions and methods for treating cancer | HRAS, KRAS, NRAS | GABRP 3806/4885GABRD 4392/4885GABRA1 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.